Hemogenyx Pharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Vladislav Sandler
Chief executive officer
UK£397.0k
Total compensation
CEO salary percentage | 98.0% |
CEO tenure | 10.9yrs |
CEO ownership | 3.1% |
Management average tenure | no data |
Board average tenure | 7.1yrs |
Recent management updates
Recent updates
Is Hemogenyx Pharmaceuticals (LON:HEMO) In A Good Position To Deliver On Growth Plans?
Aug 21Will Hemogenyx Pharmaceuticals (LON:HEMO) Spend Its Cash Wisely?
May 04We Think Hemogenyx Pharmaceuticals (LON:HEMO) Needs To Drive Business Growth Carefully
Jan 06Hemogenyx Pharmaceuticals (LON:HEMO) Has Debt But No Earnings; Should You Worry?
Oct 09CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -UK£5m |
Mar 31 2024 | n/a | n/a | -UK£6m |
Dec 31 2023 | UK£397k | UK£389k | -UK£7m |
Sep 30 2023 | n/a | n/a | -UK£7m |
Jun 30 2023 | n/a | n/a | -UK£7m |
Mar 31 2023 | n/a | n/a | -UK£6m |
Dec 31 2022 | UK£282k | UK£276k | -UK£4m |
Sep 30 2022 | n/a | n/a | -UK£3m |
Jun 30 2022 | n/a | n/a | -UK£3m |
Mar 31 2022 | n/a | n/a | -UK£4m |
Dec 31 2021 | UK£213k | UK£206k | -UK£5m |
Sep 30 2021 | n/a | n/a | -UK£5m |
Jun 30 2021 | n/a | n/a | -UK£5m |
Mar 31 2021 | n/a | n/a | -UK£3m |
Dec 31 2020 | UK£205k | UK£200k | -UK£2m |
Sep 30 2020 | n/a | n/a | -UK£2m |
Jun 30 2020 | n/a | n/a | -UK£2m |
Mar 31 2020 | n/a | n/a | -UK£2m |
Dec 31 2019 | UK£149k | UK£145k | -UK£1m |
Sep 30 2019 | n/a | n/a | -UK£2m |
Jun 30 2019 | n/a | n/a | -UK£2m |
Mar 31 2019 | n/a | n/a | -UK£2m |
Dec 31 2018 | UK£98k | UK£94k | -UK£2m |
Sep 30 2018 | n/a | n/a | -UK£2m |
Jun 30 2018 | n/a | n/a | -UK£3m |
Mar 31 2018 | n/a | n/a | -UK£3m |
Dec 31 2017 | UK£79k | UK£79k | -UK£2m |
Compensation vs Market: Vladislav's total compensation ($USD514.24K) is above average for companies of similar size in the UK market ($USD369.71K).
Compensation vs Earnings: Vladislav's compensation has increased whilst the company is unprofitable.
CEO
Vladislav Sandler (59 yo)
10.9yrs
Tenure
UK£397,000
Compensation
Dr. Vladislav Sandler, Ph D., is a Co-Founder of Hemogenyx Pharmaceuticals Plc. and serves as its Chief Executive Officer since December 2013 and serves as its Director.Dr. Sandler also serves as Chief Ex...
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 7.1yrs | UK£397.00k | 3.1% £ 550.5k | |
Independent Co-Founder & Non-Executive Director | 7.1yrs | UK£60.00k | 5.6% £ 995.0k | |
Clinical Advisor & Medical Director | no data | no data | no data | |
Member of Scientific Advisory Board | 6.7yrs | no data | no data | |
Independent Non-Executive Director | 9.3yrs | UK£50.00k | 0.42% £ 74.2k | |
Independent Chairman & Chairman of Advisory Board | 7.2yrs | UK£15.00k | no data |
7.1yrs
Average Tenure
74yo
Average Age
Experienced Board: HEMO's board of directors are considered experienced (7.1 years average tenure).